Immutep (ASX:IMM) - CEO, Marc Voigt
CEO, Marc Voigt
Source: Terrapinn Asia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • The European Patent Office has granted Immutep (IMM) protection for its Combined Preparations for the Treatment of Cancer until 2036
  • The patent specifically covers the company’s lead active immunotherapy candidate efti, which IMM describes as an antigen-presenting cell activator being explored in cancer and infectious disease
  • Immutep said the new divisional patent covers the combination of active ingredients being evaluated in its ongoing clinical trials
  • Immutep’s Chief Executive Officer Marc Voigt said building a robust patent estate was a priority for the company
  • Immutep shares are down 2.86 per cent to trade at 68 cents

The European Patent Office has granted Immutep (IMM) protection for its Combined Preparations for the Treatment of Cancer until 2036.

The patent specifically covers lead active immunotherapy candidate eftilagimod alpha (efti), which is a soluble LAG-3 fusion protein (LAG-3Ig), and a PD-L1 inhibitor – the claims also relate to methods in treating cancer.

IMM’s lead candidate, efti, is described as an antigen-presenting cell activator being explored in cancer and infectious disease. Concurrently, Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

IMM said this particular patent was filed as a divisional application and follows the grant of the European parent patent announced in November 2018, and the corresponding United States patents announced in December 2020 and March 2021.

More broadly, the ASX-lister explains the new divisional patent covers the combination of active ingredients being evaluated in its ongoing clinical trials.

Immutep’s Chief Executive Officer Marc Voigt said building a robust patent estate was a priority for the company.

“It [the patent] also highlights the critical investments we are making to protect
efti which underpin further clinical development and commercialisation of this asset,” he explained.

“Building a robust patent estate is a priority for our business and a key part of the process of bringing innovative medicines to the market to ultimately improve patient outcomes,” he concluded.

Immutep shares are down 2.86 per cent to trade at 68 cents at 3:11 pm AEST.

IMM by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…